VCYT · Veracyte, Inc.

Current Thesis

Veracyte's recovery case rests on profitable diagnostics growth, but the immediate test is whether the shares can recover the August reference close before recording another weekly decline below the September reference close. The limited recovery hypothesis requires a weekly close above $41.25, the 2026-08-14 close, before a weekly close below $39.80, the 2026-09-18 close. This is a new price-repair hypothesis; the earlier breakout thesis has failed.

The material change since the 2026-09-06 note is Veracyte's acquisition of Convergent Genomics, completed on 2026-09-14 for $150 million in upfront cash consideration, subject to customary adjustments. That expands the urology portfolio, but the acquisition does not itself demonstrate renewed demand for the shares. Veracyte's September 14 Form 8-K.

As an interpretation of market structure, the narrative is dead — the July breakout and subsequent stabilization case had both failed by the 2026-09-18 close of $39.80, below the previously published $50 invalidation and $40 deterioration condition. This describes the former market narrative, not the viability of the business. The new recovery hypothesis has low conviction because the supplied price record establishes deterioration without establishing a replacement base.

Bullish and bearish views on Veracyte, Inc.

The model's bull view on Veracyte, Inc. (VCYT), in brief: Testing growth remains measurable. Veracyte's 2026-07-30 second-quarter results reported total revenue of $150.3 million, up 15% year over year, and testing revenue of $145.7 million, up 19%. Those results support the diagnostics growth component of the case; another Decipher… The bear view: Decipher growth has already slowed. The 2026-07-30 earnings call reported second-quarter Decipher revenue growth of 20% year over year, against 30% in the first quarter. Management also removed approximately 1,000 tests from its annual Decipher volume guidance, citing the… Both cases follow in full.

Bull Case

• Testing growth remains measurable. Veracyte's 2026-07-30 second-quarter results reported total revenue of $150.3 million, up 15% year over year, and testing revenue of $145.7 million, up 19%. Those results support the diagnostics growth component of the case; another Decipher slowdown would weaken it.
• Profitability supports the operating case. The 2026-07-30 results reported $25.5 million in net income under generally accepted accounting principles and raised full-year revenue guidance to $590–596 million. A subsequent reduction below that guidance range would contradict the operating premise.
• Acquisition expands the test portfolio. The 2026-09-14 announcement added UroAmp's urinary tumor DNA platform. Management said Convergent's ongoing operating expenses were already included in its 2026 adjusted earnings before interest, taxes, depreciation and amortization guidance, which remained unchanged. Company acquisition announcement.

Bear Case

• Decipher growth has already slowed. The 2026-07-30 earnings call reported second-quarter Decipher revenue growth of 20% year over year, against 30% in the first quarter. Management also removed approximately 1,000 tests from its annual Decipher volume guidance, citing the National Comprehensive Cancer Network's earlier active-surveillance guideline change.
• Commercialization remains years away. In its 2026-09-14 announcement, management projected the first UroAmp product's commercialization in late 2028, subject to reimbursement timing. A delay beyond that window would invalidate that timetable; it is management's projection, not measured revenue. Company acquisition announcement.
• The former stabilization condition failed. The adjusted market close of $39.80 on Friday, 2026-09-18, was below the previous note's $40 weekly deterioration condition. That failure remains part of the record; the new reference-close test does not reverse it.

Setup & Price Structure

The supplied adjusted daily series records a 2026-09-18 close of $39.80, a three-month price decline of 25.2%, and a distance of 34.2% below the reported 52-week high of $60.49. The 14-period relative strength index was 37.8. These are measured price observations; they do not establish selling exhaustion.

The $41.25 close on 2026-08-14 is the first recovery reference used here. The $39.80 close on 2026-09-18 defines the prospective failure condition for this limited hypothesis, rather than a demonstrated support shelf. Success requires a weekly close above $41.25 before a subsequent weekly close below $39.80.

Coverage remains visible despite the weak price record: Benzinga reports that UBS raised its analyst target from $52 to $65 on 2026-09-09 and Freedom Capital Markets maintained $66 on 2026-09-15. These are third-party forecasts, not evidence of purchases or fund inflows. No quantified retail participation, short-interest series or moving-average distance is available in the evidence reviewed, so a crowding conclusion is unsupported. Benzinga analyst-action table.

Catalyst Calendar (next 30 days)

• 2026-09-20 through 2026-10-20: No upcoming event appears on Veracyte's investor calendar as checked on 2026-09-20. The third-quarter results date is not company-confirmed there, so no dated earnings catalyst is assigned to this window. Company events calendar.

The calendar lists the 2026-09-15 Morgan Stanley conference appearance as a past event. Its passage is not evidence that reimbursement or demand questions were resolved. The next quarterly report remains the fundamental checkpoint for comparison with the Decipher growth disclosed on 2026-07-30, but an exact release date is unavailable.

What Would Change Our Mind

Failure to retain the September reference close would end the limited repair hypothesis: a weekly close below $39.80 would invalidate it. Conversely, a weekly close above the 2026-08-14 reference close of $41.25 before that breach would satisfy the stated price-repair case; it would not establish a return to the July breakout.

The operating interpretation has a separate test. Third-quarter Decipher revenue growth below the 20% year-over-year rate reported on 2026-07-30, or another annual volume reduction, would contradict stabilization. Growth at or above that rate without another volume reduction would support stabilization, while leaving the acquisition's commercialization question unresolved.

Correlation Notes

This remains a single-company hypothesis: the available record contains no matched peer-return series from which to establish a diagnostics-sector correlation. The 2026-07-30 Decipher guidance reduction identifies a specific guideline exposure, while the 2026-09-14 acquisition announcement makes reimbursement timing relevant to UroAmp commercialization. Those are company operating dependencies; neither establishes how Veracyte's shares will move with another stock.